Cargando…

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-known consequence of PIs, most frequently reported with earlier generations such as bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN with the n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mina, Syeda A., Muhsen, Ibrahim N., Burns, Ethan A., Sarfraz, Humaira, Pingali, Sai Ravi, Xu, Jiaqiong, Hashmi, Shahrukh K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386311/ https://www.ncbi.nlm.nih.gov/pubmed/34190655 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0052

Ejemplares similares

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

A Case of Histiocytic Sarcoma Arising from Mycosis Fungoides
por: Burns, Ethan A., et al.
Publicado: (2019)

Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature
por: Kasparian, Saro, et al.
Publicado: (2020)

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
por: Kim, Kyung Bo
Publicado: (2021)

Artificial Intelligence Approaches in Hematopoietic Cell Transplantation: A Review of the Current Status and Future Directions
por: Muhsen, Ibrahim N., et al.
Publicado: (2018)

Macrophage Activation Syndrome Secondary to Underlying Sarcoidosis
por: Kasparian, Saro, et al.
Publicado: (2019)

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
por: Burns, Ethan A., et al.
Publicado: (2021)

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Burns, Ethan A., et al.
Publicado: (2021)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases
por: Burns, Ethan A, et al.
Publicado: (2020)

Machine Learning Applications in the Diagnosis of Benign and Malignant Hematological Diseases
por: Muhsen, Ibrahim N., et al.
Publicado: (2020)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
por: Su, Pan, et al.
Publicado: (2022)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
por: Lee, Sarah, et al.
Publicado: (2023)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Breast Cancer Metastasis Masquerading as a Primary Gynecological / Colonic Malignancy: A Rare Diagnostic Conundrum
por: Sarfraz, Humaira, et al.
Publicado: (2020)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Quality of Life in Hematologic Malignancy in the Eastern Mediterranean Region: A Systematic Review
por: Alhamss, Marwa M, et al.
Publicado: (2022)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

Primary CNS Lymphoma Arising from the 4(th) Ventricle: A Case Report and Review of the Literature
por: Brozovich, Ava, et al.
Publicado: (2019)

Antibacterial‐associated acute kidney injury among older adults: A post‐marketing surveillance study using the FDA adverse events reporting system
por: Chinzowu, Tichawona, et al.
Publicado: (2022)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
por: Altebainawi, Ali F., et al.
Publicado: (2023)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

The next forum for unraveling FDA off-label marketing rules: State and federal legislatures
por: Sinha, Michael S., et al.
Publicado: (2018)

Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing Applications
por: Agyeman, Abena S., et al.
Publicado: (2022)

Inclusion of patient-reported outcome instruments in US FDA medical device marketing authorizations
por: Matts, Sophia T., et al.
Publicado: (2022)

Clinical Trial Diversity in Oncology: FDA Takes Action with Post–Marketing Requirements or Commitments
por: Kim, Janice, et al.
Publicado: (2022)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Nutritional outcomes of empowerment and market integration for women in rural India
por: Gupta, Soumya, et al.
Publicado: (2019)

IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers
por: Berg, Carla J., et al.
Publicado: (2021)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tctrt7mrhhpdip41vlpm8as751